Key Figures Q3 2023

SEK m, unless otherwise stated

2023
Jul-Sep

2022
Jul-Sep

2023
Jan-Sep

2022
Jan-Sep

% Change

2022
Jan-Dec

 

Net revenues 156.1 161.0 472.8 468.3 1.0% 624.3  
Cost of goods sold -22.8 -28.0 -68.8 -76.7 -10.3% -102.6  
Operating expenses -161.9 -182.8 -505.0 -504.3 0.1% -705.6  
EBIT -28.6 -49.8 -100.9 -112.8 -10.5% -183.9  
EBIT margin, % -18.4% -31.0% -21.3% -24.1% -11.6% -29.5%  
EBITDA -9.5 -32.4 -44.8 -62.1 -27.9% -115.2  
Earnings per share, before dilution, SEK -0.97 -0.77 -3.19 -2.50 27.6% -5.17  
Earnings per share, after dilution, SEK -0.97 -0.77 -3.19 -2.50 27.6% -5.17  
Cash flow from operating activities -21.9 -60.7 -92.4 -107.8 -14.3% -156.6  
Cash and invested funds 184.2 443.9 184.2 443.9 -58.5% 351.9  


Net revenues and EBIT per segment Q3 2023

 

Net Revenues

EBIT


SEK m

2023
Jul-Sep

2022
Jul-Sep

2023
Jan-Sep

2022
Jan-Sep

2022
Jan-Dec

2023
Jul-Sep

2022
Jul-Sep

2023
Jan-Sep

2022
Jan-Sep

2022
Jan-Dec

ZUBSOLV® US 140.4 150.1 426.3 428.8 571.4 - - - - -
US Pharma – total 140.4 150.1 426.3 428.8 571.4 62.3 70.2 207.7 231.4 308.4
Digital Therapeutics (DTx) product sales 0.0 0.1 0.1 0.3 0.4 - - - - -
Digital Therapeutics (DTx) – total 0.0 0.1 0.1 0.3 0.4 -31.6 -48.9 -101.8 -140.1 -189.1
Abstral® royalties 7.7 7.5 21.9 24.9 30.4 - - - - -
Edluar® royalties 3.5 2.9 8.8 7.7 10.4 - - - - -
ZUBSOLV® - ex US 4.5 0.4 15.6 6.5 11.8 - - - - -
HQ & Pipeline - total 15.7 10.8 46.4 39.1 52.6 -59.3 -71.2 -206.9 -204.0 -303.2
Total 156.1 161.0 472.8 468.3 624.3 -28.6 -49.8 -100.9 -112.8 -183.9


Cash flow Q3 2023


SEK m

2023
Jul-Sep

2022
Jul-Sep

2023
Jan-Sep

2022
Jan-Sep

2022
Jan-Dec

Cash flow from operating activities -21.9 -60.7 -92.4 -107.8 -156.6
Investment activities -6.6 -69.0 201.7 -300.9 -234.7
Financing activities -39.1 -5.0 -64.6 -15.6 -21.4
Cash flow (excl exchange rate differences) -67.6 -134.7 44.7 -424.3 -412.8
Cash and cash equivalents 184.2 122.4 184.2 122.4 132.2